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If in doubt, give the patient the benefit of the doubt.” Dr Robert Ginsbergtaught me this while I trained with him in the early 1990s at MemorialSloan-Kettering Cancer Center. Since that moment, I have adhered to thisprinciple, with frequent significant benefit to my patients.
Noninvasive radiologic preoperative staging of non–small cell lung cancer
(NSCLC) has dramatically changed over the past decade. High-resolution spiral
computed tomography (CT) can now delineate nearly all enlarged hilar and medi-
astinal lymph nodes and can detect other lung nodules as small as 1.0 mm. Positron
emission tomography (PET) scanning now provides a whole-body image search for
metastases. Whether CT or PET is used, a problem arises when a result is equivo-
cal or uncertain. With PET scanning, the answer to a negative result may be easy—
operate. A positive result, however, may open a Pandora’s box of clinical
interpretations, ranging from obviously positive (eg, a definite hot spot on a rib), to
a faint smudge of positivity (with the surgeon asking the radiologist, “Do you think
there is anything really there?”), to errors of interpretation (eg, kidney, renal col-
lecting ducts, bladder, liver). This frequent haze of uncertainty is a regular event
with radiologic results.
The article by Buccheri and Ferrigno1 attempts to improve on the accuracy of
preoperative radiologic evaluation with a simple serum test for two tumor markers:
tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA). TPA, a
member of the cytokeratin family, consists of proteolytic fragments of the cytoker-
atins 8, 18, and 19. Because TPA is made up of cytoskeleton fragments, elevated lev-
els tend to represent increased cell division and turnover of a tumor. Hypothetically,
larger, more advanced tumors may have higher cell division and death rates, with
correspondingly higher levels of serum TPA. CEA, a cell-surface glycoprotein of the
immunoglobulin gene superfamily, is normally expressed in secretory tissues. CEA
may be important for intercellular adhesion and attachment; through those functions
it is thought to be potentially involved in tumor cell metastasis.
In the study by Buccheri and Ferrigno, 124 consecutive patients—whose
NSCLC had been staged primarily by chest, abdominal, and brain CT (with no PET
and only rare mediastinoscopy)—underwent surgical resection. Preoperative serum
TPA and CEA levels were correlated with surgical resectability, defined as “patho-
logic postoperative documentation of stage Ia through IIb disease.” The indepen-
dent accuracy of CT (chest, abdominal, brain) in predicting surgical resectability
was 77%; that of TPA levels, 65%; and that of CEA levels, 69%. Low levels of TPA
(<90 U/L) and CEA (<10 ng/mL) increased the accuracy of CT to 83% and 85%,
respectively. Conversely, elevated levels of TPA and CEA increased the accuracy of
CT to 89% and 100%.
Buccheri and Ferrigno defined a cutoff for resectability at the IIb to IIIa point.
This cutoff represents relatively advanced disease, most of which would now be
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detected with PET scanning and mediastinoscopy. Although
serum measurements of various tumor markers such as TPA
and CEA may incrementally improve staging accuracy, par-
ticularly with more advanced disease, a gray zone of uncer-
tainty still remains that can be dispelled only by tissue
staging.
The search for a more accurate means of preoperative stag-
ing is entering a new and exciting phase, ushered in by
advances in molecular biology. With PCR techniques, occult
micrometastatic tumor cells can now be detected in histologi-
cally normal lymph nodes, bone marrow, or blood. In addition,
with quantitative PCR, the number of occult micrometastatic
tumor cells in a given tissue sample can now be quantitated.
Two current trials, the Cancer and Leukemia Group B 9761
and the American College of Surgeons Oncology Group, are
now in the process of evaluating the detection of occult
micrometastases in patients with NSCLC. The results of these
two trials will shed light on the predictive value of such mole-
cular techniques. The ability to preoperatively determine a
patient’s micrometastatic tumor burden would fundamentally
alter preoperative evaluation and treatment planning.
About 50% of patients with lung cancer now die within
5 years after curative-intent resection. Clearly, our current
ability to detect unfavorable tumor biology and dissemi-
nated malignant disease is limited. Until molecular-based
techniques are routinely available, which will occur, the
onus is still on the thoracic surgeon to give the patient the
benefit of the doubt.
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